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Severe combined immunodeficiencies (SCIDs) are a group of inherited disorders responsible for severe dysfunctions
of the immune system.These diseases are life-threateningwhen the diagnosis ismade too late; they are themost severe
formsof primary immunodeficiency. SCIDpatients oftendie during thefirst twoyears of life if appropriate treatments
to reconstitute their immune system are not undertaken. Conventionally, SCIDs are classified according either to the
main pathway affected by the molecular defect or on the basis of the specific immunologic phenotype that reflects
the stage where the blockage occurs during the differentiation process. However, during the last few years many new
causative gene alterations have been associated with unusual clinical and immunological phenotypes. Many of these
novel forms of SCID also show extra-hematopoietic alterations, leading to complex phenotypes characterized by a
functional impairment of several organs, which may lead to a considerable delay in the diagnosis. Here we review
the biological and clinical features of SCIDs paying particular attention to the most recently identified forms and to
their unusual or extra-immunological clinical features.
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Introduction
Severe combined immunodeficiencies (SCIDs) are
a group of inherited disorders responsible for se-
vere dysfunctions of the immune system that lead
to the absence or dysfunction of the T and B cells
derived from the thymus gland and bone marrow,
thus affecting both cellular and humoral adaptive
immunity. Recently, Kwan et al., on the basis of data
obtained from 11U.S. newborn screening programs
in the general population, reported an incidence of
SCID of 1 in 58,000 live-births, an incidence much
higher than the previous estimate of one in 100,000
based on retrospective clinical diagnosis of SCID.1
This group of diseases belongs to the most severe
forms of primary immunodeficiency (PID), which
are often fatal when the diagnosis is made too late.2
Even though children with SCID appear healthy at
birth, they are predisposed to severe bacterial, vi-
ral, and fungal infections as the maternal trans-
ferredantibodiesdecline.During thefirst yearof life,
failure to thrive, diarrhea, and oral candidiasis are
common findings; Pneumocystis jiroveci may fre-
quently cause a severe interstitial pneumopathy;
andmaternal engraftment of lymphocytes can cause
graft-versus-host disease (GVHD).3 SCID patients
often die during the first two years of life if appropri-
ate treatments to reconstitute their immune system
are not undertaken.4 For most patients, the only
curative treatment is the allogeneic hematopoietic
stem cell transplantation (HSCT).5 Gene therapy
offers a cure for two specific forms of SCID and,
although other SCID forms may become amenable
to this treatment in the future, it is likely that HSCT
will continue to be used for the majority of SCID
patients.6
Conventionally, SCIDs canbe classified according
either to the main pathways affected by the molecu-
lar defect or on the basis of the specific immunologic
phenotype related to that genetic defect, as T cell–
deficient but normal B cell (T−B+) SCID and both
T cell– and B cell–deficient (T−B−) SCID, with a
further subdivision depending on the presence or
doi: 10.1111/nyas.12849
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absence of NK cells (NK+ or NK–, respectively).2
This classification, traditionally considered as rep-
resentative of the stage where the blockage occurs
during the differentiation process, was, until a few
years ago, very useful in directing molecular studies
toward a certain genetic alteration.However, during
the last years many new causative gene alterations
have been identified with peculiar clinical and im-
munological phenotypes. In a few cases, the genetic
alteration allows for a normal T cell differentiation
program but compromises T cell functionality by
affecting the initial or final phase of intracellular
signaling. These functional T cell disorders are
characterized by immune dysregulation and cancer
predisposition, as well as infections. In addition,
hypomorphic mutations in some SCIDs genes
make possible the development of nonfunctional
oligoclonal T cells that are responsible for a complex
of clinical conditions thatmay include hyperinflam-
mation or autoimmunity. Many of the novel forms
of SCID also show extra-hematopoietic alterations,
leading to complex phenotypes characterized by
functional impairment of organs different from
primary lymphoid organs, which can make the
diagnostic process very complex by standard
methods. Taking this into account, the traditional
international classification of SCIDs based on
immunophenotype may no longer be optimal
for clinical and research purposes7,8––diagnostic
criteria have to be continuously updated to take into
account these unusual phenotypic presentations. In
his work of 2014, Shearer emphasizes that currently
there is no consensus among clinical immunologists
on how best to diagnose and treat these rare disor-
ders. It is not surprising that an important clinical
dilemma concerns the distinction of SCIDs from
other diseases such as combined immunodeficien-
cies (CIDs). Recently, it was proposed that patients
who exhibit an absence or a severe reduction of
T cells (CD3+ < 300/L), absence or severe reduc-
tion (<10% of the lower limit) of a proliferative
response to phytohemagglutinin, or a maternal
lymphocyte engraftment should be defined as hav-
ing typical SCID.5 Moreover, the European Society
for Immunodeficiency suggested as criteria for the
diagnosis ofCID thepresence of oneof the following
parameters: one severe infection, an immunodys-
regulation disorder, cancer, familial CID associated
with moderate age-related reduction of CD3+,
CD4+, CD8+ T cells or of naive T cells. However,
a cutoff to distinguish SCID from CID has not yet
been well defined.
A main aim of this review is to report on the
biological and clinical features of SCID, paying at-
tention to the most recently identified forms and
to the unusual or extra-immunological clinical fea-
tures (Table 2). An attempt to relate together patho-
genetic mechanisms to specific clinical features is
proposed (Table 1).
SCID due to defective survival of
hematopoietic lineage precursors
Reticular dysgenesis (RD) is an autosomal recessive
form of SCID characterized by both early myeloid
lineage differentiation arrest and impaired lym-
phoid development.9 It is considered the most se-
vere form of SCID, accounting for less than 2%. A
peculiarity of this disorder is the presence of sen-
sorineural deafness. RD is caused by biallelic muta-
tions in the adenylate kinase 2 gene (AK2), which
cause the absence or the strong reduction of the
expressionofAK2protein.9,10 The syndrome is char-
acterized by the absence of granulocytes and lym-
phocytes in peripheral blood. Compared to all the
other forms of SCID, RD-associated neutropenia,
which is unresponsive to granulocyte-colony stim-
ulating factor (G-CSF), predisposes the patients to
severe infections.11 The only available treatment for
RD is allogeneic HSCT, which indicates that the
inherited defect is cellular and not linked to the
micro-environment, as previously thought. Neu-
trophil differentiation abnormalities of RD patients
are corrected by the restoration of AK2 expression
in the bone marrow, thus confirming the specific
role of AK2 in the development of the myeloid
lineage.12 Moreover, AK2 is specifically expressed in
the stria vascularis region of the inner ear, which ex-
plains the sensorineural deafness observed in these
individuals.10 AK2 is localized in the mitochondrial
intermembrane space where it regulates adenine
nucleotide interconversion within the intermem-
brane space;13 a very similar function is mediated
by the cytoplasmatic enzyme AK1. The function
of AK1/2 is classically described to be the main-
tenance of a constant concentration of adenine
nucleotides and the monitoring of mitochondrial
energy state through a finemechanismof nucleotide
sensing and signaling. The molecule also plays a
central role in the control of apoptosis through the
Fas-associated protein with death domain (FADD)
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Table 1. New clinical phenotypes associated with old forms of nonsyndromic SCID/CID and new genetic defects
Gene defect Old phenotype New phenotype Pathogenetic mechanism
Reference
AK2 Absence of granulocytes, severe
lymphopenia sensorineural
deafness
OS Peripheral expansion of
oligoclonal T lymphocytes
15
IL2RG (c)
JAK3
T–B+NK– SCID, leaky T+B+NK–
SCID, immune-dysregulation
and autoimmunity
Hodgkin like features,
invagination and HLH
Selective CD4+
T lymphopenia
Not clear; maternal GVHD
Hypomorphic mutation
associated with somatic
chimerism
55,56
51
RAG Severe hypogamma-
globulinemia, marked
reduction of T and B cells, OS,
incomplete OS
Granulomatous lesions,
EBV-related lymphoma,
Idiopatic CD4+ T
lymphopenia with
extensive chickenpox
Hypomorphic mutations 70
CORO1A T–B–NK+ SCID, severe
postvaccination chickenpox,
language delay, behavioral and
cognitive impairment
EBV B cell
lymphoproliferation
Not clear; null and
hypomorphic mutations
of Coro1A in mice are
associated with defects
in T cell survival and
migration
79
FOXN1 Human nude/SCID Eczematous rash,
erythroderma, severe
diarrhea and alopecia
Residual T cell development
sustained by rudimentary
thymus or extrathymic
lymphoid sites
80
IL21R NA Cryptosporidiosis, chronic
cholangitis and liver
disease, abnormal IL-21
induced proliferation,
defect of immunoglobulin
class-switching, and NK
cell cytotoxicity
Abrogation of IL-21 ligand
binding, defective
cytokine secretion
99
ZAP70 Selective CD8+ lymphopenia and
normal/elevated numbers of
not functional CD4+ T cells
Late onset disease, cutaneous,
erythematous lesions,
immune dysregulation
erythroderma
Possible role of hypomorphic
mutations on T
lymphocytes effector and
suppressive function
113
MALT1 NA CID Abnormal IL-12 production,
failure of IB degradation
114
BCL10 NA Profound T and B memory
cell deficiency, severe
hypogammaglobulinemia
Impairment of NF-B
pathways
115
CARD11 NA CID Abnormal IL-12 production,
Treg cells deficiency
101
TTC7A NA CID-MIA Defective thymopoiesis 116
LCK, UNC119 NA CD4+ lymphopenia,
restricted T cell repertoire,
immune dysregulation
Impaired TCR signaling 122
IKBK2 NA Mycobacterium avium and
tuberculosis infections,
neurological impairment,
hypogammaglobulinemia,
normal T cells count with
absence of Treg and  /
T cells
Impairment of IKK2–NF-B
signaling
124
Note: OS, Omenn syndrome; HLA, hemophagocytic lymphohistiocytosis, GVHD, graft versus host disease; MIA,
multiple intestinal atresia; NA, not applicable.
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Table 2. Pathogenetic mechanisms of SCID
Pathogenetic mechanism Defect Phenotype Inheritance
Defective survival of haematopoietic
precursors
AK2 T–B–NK– AR
Toxic metabolite accumulation ADA T–B–NK– AR
PNP T–B+NK– AR
Cytokine signaling anomalies IL-2RG T–B+NK– XL
JAK3 T–B+NK– AR
IL-7RA T–B+NK+ AR
V(D)J recombination and TCR
abnormalities
RAG1/RAG2, Artemis,
DNA-PKcs, Cernunnos,
LIG4
T–B–NK+ AR
TCR abnormalities CD45 T–B+NK+ AR
CD3ε, ,  T–B+NK+ AR
CORO1A T–B–NK+ AR
Thymic abnormalities FOXN1 T–/lowB+NK+ AR
DiGeorge sindrome T–B+NK+ De novo or AD
and caspase 10 pathways.14 Omenn syndrome (OS),
resulting from residual development and periph-
eral expansion of oligoclonal T lymphocytes, has
recently been described in a patient with RD due
to missense mutation in AK2.15 OS is a clinical
condition characterized by generalized skin rash,
hepatomegaly, splenomegaly, lymphadenopathy
(similar to that which occurs in SCID patients
with detectable CD3+ T cells), absent or low
T cell proliferation to common antigens, and no
maternal engraftment. Increased IgE serum levels
and eosinophil count are also common features.
In rare patients with RD, no mutations in AK2
have been found, suggesting a potential role for
other molecules involved in this pathway. For in-
stance, a similar phenotype has been described in
a murine models either deficient for growth factor
independence-1 (Gfi-1) or transgenic for expression
of Gfi-1b nucleoproteins, suggesting a role for these
two factors in the pathogenesis of RD.16
SCID due to accumulation of toxic
metabolites
Adenosine deaminase (ADA) deficiency and purine
nucleoside phosphorylase (PNP) deficiency are
inherited disorders of the purine metabolism char-
acterized by abnormal accumulation of toxic nucle-
oside products.17 ADA deficiency is responsible for
a T cell–, B cell–, and NK cell–deficient (T–B–NK–)
form of SCID associated with thymic hypoplasia
and absence of lymphocyte proliferative response.
Before the introduction of newborn screening, the
incidence of this autosomal recessive disorder was
estimated tobebetween1:375,000and1:660,000 live
births.18 However, a recent trial on a population-
based neonatal screening revealed that the inci-
dence of ADA-SCID is much higher, and closer to
1:50,000.19 The ADA gene of 12 exons is located in
a 32 kb region on chromosome 20q13.11. Several
genetic alterations, with more than seventy muta-
tions, have been identified in ADA-SCID patients.20
The product of ADA is an ubiquitous enzyme that
catalyzes the irreversible deamination of adenosine
(Ado) and deoxyadenosine (dAdo) to inosine and
deoxyinosine, respectively. Despite ADAprotein be-
ing present in virtually every cell of the humanbody,
it is particularly expressed in the lymphoid system,
especially in the thymus, where it plays a key role in
its differentiation and maturation. The absence of
ADA activity is responsible for a massive accumula-
tion of Ado and dAdo, in particular in thymocytes,
lymphocytes, and erythrocytes.17,21 dAdo phospho-
rylation by nucleoside kinases leads to the pro-
duction of deoxynucleotide triphosphates (dATP)
whose accumulation, altering lymphocyte signaling
pathways and serving as a danger signal, may cause
the severe lymphopenia observed inADAdeficiency.
Another alternative pathogenic mechanism pro-
posed is the inhibition of S-adenosylmethionine–
mediated transmethylation reactions required for
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cell viability and normal differentiation.22 By the
first 6monthsof ageup to80%ofpatients showmul-
tiple recurrent opportunistic infections that rapidly
may become fatal and hypoplasia or apparent ab-
sence of lymphoid tissue. However, in the remain-
ing patients, a late-onset phenotype, presenting at
two or three years of life, or even later,23 has been
reported. These patients may also present with au-
toimmune diseases and usually exhibit a milder T
cell immunodeficiency, which gradually progresses.
Owing to its ubiquitous expression normally, ADA
deficiency can affect several organs, leading to the
development of skeletal alterations, such as anterior
rib cupping, scapular spurring, and pelvic dyspla-
sia, which can be reversible with appropriate ther-
apy. In addition, pulmonary alveolar proteinosis,
probably caused by a surfactant metabolism defect,
and hepatic, gastrointestinal, and neurological dis-
orders, mainly due to Purkinje cell damage, may be
found. Bone marrow hypocellularity and myeloid
dysplasia also have been observed in some ADA-
deficient patients; in others, renal impairment.24,25
A genotype–phenotype correlation has been docu-
mented and, in particular, severity of disease seems
to correlate with residual ADA activity and the types
of substrates that accumulate.26 The therapeutic ap-
proach currently available for this particular formof
SCID includes three options: enzyme replacement
therapy with polyethylene glycol-modified bovine
adenosine deaminase, HSCT, or gene therapy.27–29
The use of dried blood spot samples tested by tan-
demmass spectrometry has been recently proposed
as part of a neonatal program of screening in several
countries.
Purine nucleoside phosphorylase gene (PNP)
mutations result in an extremely rare autosomal
recessive disorder accounting for 4% of all form
of SCIDs.30 Autoimmunity, recurrent infections,
failure to thrive, and neurologic dysfunction are
some of the main features of PNP deficiency. PNP
maps to chromosome 14q13 and encodes a pro-
tein that catalyzes the phosphorolysis of guano-
sine, deoxyguanosine, inosine, and deoxyinosine,
to their respective purine bases.17,31,32 Mutations in
the PNP pathways result in elevated deoxyguano-
sine triphosphate storage and in T cell toxicity due
to the inhibition of the mechanisms of DNA syn-
thesis and repair, resulting in an increased sensitiv-
ity to DNA damage and apoptosis, especially in T
lymphocytes during selection within the thymus.33
T cell defects typically become evident by the first
year of life, with a milder phenotype than what is
normally seen in ADA deficiency. PNP deficiency
can be suspected when lymphopenia is associated
with reduced PNP enzymatic activity in red blood
cells in a patient with recurrent respiratory infec-
tions and other typicalmanifestations.34 Low serum
uric acid (hypouricemia) is usually found, although
PNP deficiency should not be ruled out if patients
do not exhibit it. The immunodeficiency in these
patients is progressive, since the severe T cell de-
ficiency usually appears after the second year of
life and is characterized by a normal B cell com-
partment. Among the neurological disorders asso-
ciated with PNP deficiency, ataxia, developmental
delay, and spasticity have been described. Autoim-
mune diseases observed include hemolytic anemia
and sclerosing cholangitis,35 and in some patients
megaloblastic or dysplastic bone marrow has been
described.33
SCID due to cytokine signaling anomalies
Cytokines are soluble regulators of immune system
homeostasis. Alterations of their signaling are im-
plicated in the pathogenesis of the major SCIDs.
In particular, SCIDs caused by defects of the com-
mon gamma chain (c), Janus kinase 3 (JAK3), or
the IL-7 receptor  chain (IL-7R) are prototypic
cytokine-associated disorders, accounting for 67–
74% of all cases of SCIDs.36,37
Mutations of c gene cause X-linked SCID
(X-SCID), one of themost common forms of SCID,
accounting for50%of all cases.Thec gene (IL2RG)
maps to chromosome Xq13.1 and encodes a trans-
membrane protein that is a component of several
cytokine receptors, including IL-2, IL-4, IL-7, IL-9,
IL-15, and IL-21, all critical for lymphocyte devel-
opment and function.38 The c interacts with the
intracellular tyrosine kinase JAK3, which acts as a
transducing element39 indispensable for cell growth
and control of hematopoietic cell development. Ev-
idence indicates that c is widely expressed in non-
hematopoietic cells as well, even though its function
in these cells has not yet been clearly elucidated.
It has been reported that c is implicated in the
growth hormone receptor signaling, suggesting the
existence of a subtle interaction between endocrine
and immune systems.40–44
JAK3, mainly expressed in lymphoid and
myeloid cells, is essential for the differentiation of
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hematopoietic precursors;45–47 its deficiency is re-
sponsible for an autosomal recessive SCID. Molec-
ular alteration of JAK3 may affect any of its
functional domains and results in a T–B+NK–
form of SCID, with a clinical phenotype simi-
lar to that observed in c deficiency.48 The im-
munological phenotype is due to the key role of
c/JAK3 signaling in both early T and NK cell,
but not B cell, differentiation programs. However,
B cell–intrinsic abnormalities, suchas impaired class
switch recombination and defective antibody pro-
duction, have been documented. The identification
of IL-7R–deficient SCID patients with a selective
T cell defect37 implies that the T cell defect observed
in SCID due to mutations of c/JAK3 results from
defective IL-7 signaling. The ability of IL-15 to drive
NK cell development49 explains the lack of NK cells
in c/JAK3-deficient patients as a consequence of
defective IL-15 signaling.50 The molecular basis of
the B cell functional abnormalities in patients with
c/JAK3 deficiency is probably linked to a defect
in IL-21 secretion, a cytokine involved in prolifer-
ation, Ig isotype switching, plasma cell generation,
and antibody secretion through activation of the
JAK/STAT pathway.
Recently, hypomorphic mutations in JAK3 asso-
ciated with somatic chimerism have been reported
in a patient with predominant CD4+ lymphope-
nia.51 This observation suggests that hypomorphic
mutations and/or somatic chimerism inother genes,
which usually cause a SCID phenotype, eventu-
ally could be implicated in selective CD4+ lym-
phopenia. Individuals with mutations that result in
the production of a small amount of gene prod-
uct or a protein with residual activity are less fre-
quently seen. These individualsmayhave an atypical
“leaky” disease characterized by T+B+NK– pheno-
type that is associated with immune dysregulation
and autoimmunity, rashes, splenomegaly, gastroin-
testinal malabsorption, and/or short stature;52,53 a
fewpatientshavepresentedwithanOSphenotype,54
which is characterized by elevated IgE, erythro-
derma, and an expansion of cells with a lymphocyte
profile.
A peculiar extranodal lymphoproliferative dis-
order characterized by a polymorphous CD20+
B lymphocyte infiltrate, resembling Hodgkin Reed-
Sternberg cells, has also been observed in two
patients affected with X-SCID.55 Recently, a novel
mutation in exon 5 of the c gene has been reported
that causes a classical severe immunological pheno-
type associated with invagination and hemophago-
cytic lymphohistiocytosis (HLH).56 The HLH
phenotype, previously described in two other cases
with c gene mutations,57 is probably explained by
maternal GVHD, and highlights the need for a fine-
grained evaluationof the immunological phenotype
and associated genotypes in patients with HLH.58
As for the mechanism by which maternal engrafted
T cells may be responsible for HLH in such cases, it
is reasonable to hypothesize that unchecked T cell
dysregulation of CD8+ cells, activated by alloanti-
gens, may result in cytokine hypersecretion and
massive macrophage activation, eventually leading
to hemophagocytosis.
The mutations of IL-7R gene (IL7R) cause a
T–B+NK+ SCID with an autosomal recessive trans-
mission that is responsible for 10% of all SCIDs.
The human IL7R maps to chromosome 5p13.2 and
encodes for a protein59 that is a component of
two cytokine receptors, namely IL-7R and thymic
stromal lymphopoietin receptor (TSLPR). Follow-
ing the binding of IL-7 to IL-7R, JAK1 (coupled
to IL-7R) and JAK3 are activated, which induces
the phosphorylation of IL-7R, the recruitment of
STAT5, and phosphatidylinositol 3-kinase (PI3K) at
the receptor signaling apparatus. STAT5 molecules
dimerize and translocate to the nucleus, leading to
the transcription of IL-7–dependent genes. PI3K
induces Akt activation, which prevents cell death
through inhibition of Bad and regulates the kinase
activity of Tor, eventually leading to the induction
of several nuclear targets, including nuclear factor
of activated T cells (NF-AT), NF-B, and cyclin D1.
Finally, activation of the Ras/MAPK/ERK pathway
results in the inductionof other nuclear targets, such
as c-Myc, STAT1/3, and the Ets transcription fac-
tors. IL-7R is almost exclusively expressed by cells of
the lymphoid lineage and is involved in thymocyte
survival and maturation, particularly during CD8+
positive selection.60
TSLPR, expressed mainly on monocytes, den-
dritic cells (DCs), and some types of T lymphocytes,
is able to activate JAK2/STAT5 pathway, although
this does not lead to cell proliferation. Human TSLP
acts primarily on DCs, promoting DC-mediated
expansion of CD4+ T lymphocytes that acquire a
memory T cell phenotype. The clinical phenotype
of this form of SCID is quite heterogeneous and in-
cludes peculiar features such as OS,61 cytopenia,62
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severe and unresponsive cytomegalovirus (CMV)
infection, or diarrhea of probable viral origin.61
SCID due to V(D)J recombination and TCR
abnormalities
V(D)J recombination is a complex process that oc-
curs in early B and T cell development. It is re-
sponsible of the introduction of site-specific DNA
double strand breaks (DSBs) by the recombina-
tion activating genes (RAG) 1 and 2.63,64 The
cleavage of the hairpin and the joining of these
segments requires the DNA nonhomologous end-
joining (NHEJ) DNA repair factors, which generate
the diversity through recombination of theV,D, and
J segments and junction.
NHEJ also plays a role in preserving the genomic
stability of cells exposed to X-ray DNA damage.
Consistent with these functions, it is not surprising
that mice lacking NHEJ components exhibit a SCID
phenotype and radiosensitivity (RS), a phenotype
referred to as RS-SCID. In humans, several muta-
tions in NHEJ genes have been identified, including
mutations in genes for DNA ligase IV (LIG4),
XLF/Cernunnos (NHEJ1), DNA-PKcs (PRKDC),
and Artemis (DCLREIC), that are associated with
SCID.64–66 Of note, the increased radiosensitivity
peculiar to these forms of SCID can be used as a
diagnostic tool.67,68
Owing to the essential role of RAG1/RAG2 genes
in V(D)J recombination,mutations ofRAG1 and/or
RAG2, associated with partial protein expression
and limited production of T and B cells, have
been associated with a T–B–NK+ SCID, OS, and
autoimmunity.69 Hypomorphic RAG gene muta-
tions have also been described in patients with gran-
uloma formation70 and EBV-related lymphoma.71
Since different clinical phenotypes have been as-
sociated with similar RAG mutations resulting in
the same biological effect, a complex pathogenetic
mechanism, based not only on the residual recom-
binase activity but also on the type and the moment
of antigenic pressure has been postulated.
Artemis deficiency causes T cell maturation and
B cell differentiation arrest at the pre-B cell check-
point, resulting in a T–B–NK+ SCID.68 DNA-PKcs
is involved in Artemis regulation and activation by
both phosphorylation and complex formation, thus
regulating enzymatic activities critical for V(D)J
recombination.64,72 Deficiency of DNA-PKcs causes
a phenotype similar to Artemis deficiency.
The deficiency of XLF/Cernunnos causes
a T–B–NK+ SCID phenotype associated with
microcephaly.73 Inparticular, the phenotype is char-
acterized by a progressive decrease of B cells and the
presence of only memory T cells. Crystallography
studies showed that XLF/Cernunnos is a compo-
nent of the LIG4/XRCC4 complex, which exerts a
role in aligning the twoDNAends in theDNA repair
complex machinery. Deficiency of LIG4 is respon-
sible for facial dysmorphisms, microcephaly, and
variable forms of PID, ranging from SCID/OS to
hypogammaglobulinemia or moderate defects in T
and B cell functions.74
Gene mutations that abrogate early TCR signal-
ing are associated with profound abnormalities of
T lymphocyte development and function. CD45
(leukocyte common antigen) is a transmembrane
tyrosine phosphatase involved in both TCR signal-
ing and T cell development within the thymus and
B cell development and maturation. CD45 de-
ficiency is responsible for a very rare form of
T–B+NK+ SCID in which lymph nodes lack germi-
nal centers.75 Despite a normal monocyte numbers,
T lymphocyte numbers are considerably decreased,
with normal expression of TCR  chains but a
reduction of TCR+ cells. B cells, even though
nonfunctional, are increased in number.
CD3 is a multimeric complex involved in TCR
signaling and required for T cell differentiation.
Defects of the complex can involve all the chains,
resulting in a T–B+NK+ phenotype. Alterations of
the subunits epsilon (CD3ε), delta (CD3), and zeta
(CD3 ), have been reported in patients with severe
forms of SCID, while alterations of the CD3 have
been associated with a more benign course. These
disorders are rare and inherited as autosomal reces-
sive SCIDs. Some mutations can allow residual T
cell maturation, even though the cross-talk between
thymocytes and thymic epithelial cells may be im-
paired, thus compromising central tolerance and
regulatory T cell (Treg) development. Autoimmune
manifestations, including autoimmune hemolytic
anemia, vitiligo, Hashimoto’s thyroiditis, autoim-
mune enteropathy, Evans syndrome, autoimmune
hepatitis, and nephrotic syndrome are frequently
observed in such patients.76
Coronin-1A is important for regulation of actin
polymerization of cytoskeleton and essential for
T cell migration from the thymus to the secondary
lymphoid organs.77 The human coronin-1A gene
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(CORO1A) maps to chromosome 16p11.2 and
encodes a highly conserved 57-kDa actin-binding
protein expressed in both hematopoietic and
immune cells. Coronin 1A–deficient neutrophils
of mice have a normal adherence, membrane
dynamics, migration, phagocytosis, and oxidative
burst; dendritic cells are similarly not impaired.
However, coronin 1A–deficient mice exhibit T cell
lymphocytopenia and a normal number of B and
NK cells, thus confirming its prominent role in
T cell homeostasis and TCR signaling. In humans,
deficiency of coronin 1A is associated with the
absence of peripheral T cells.78 However, different
from other SCIDs due to other genetic alterations,
a normal size thymus has been observed in the
context of coronin 1A deficiency.79 Hypomorphic
CORO1A mutations have been associated with
aggressive Epstein Barr virus–associated B cell
lymphoproliferation, occurring at an early age.79
SCID due to thymic abnormalities: from
DiGeorge syndrome to nude/SCID
The prototype of athymic disorders caused by
abnormalities of the stromal component of the
thymus––the primary lymphoid organ for T cell
differentiation––is the nude/SCID syndrome, de-
scribed in humans in 1996.80 This form of SCID is
the only one not primarily related to an intrinsic
abnormality of the hematopoietic cell, but rather
to a defect in hematopoietic cell–supporting thymic
epithelial cells.81–83 This human SCID is the equiva-
lent of the murine nude/SCID phenotype described
in 1966, although in humans the phenotype is more
severe. It is one of the rarest forms of SCID, and
only three mutations have been associated thus far
with nude/SCID.84 The gene responsible for the
disease in humans is FOXN1, located on chromo-
some 17,85 which encodes a member of the fork-
head/winged helix class proteins; this same gene is
mutated in the same type of SCID in mice and rats.
Forkhead/winged helix proteins is a large family of
transcriptional factors implicated in several biolog-
ical processes governing development, metabolism,
cancer, and aging. FOXN1 ismainly expressed in the
epithelial cells of the skin and thymus, where it plays
a role in maintaining the balance between growth
and differentiation. Thymic epithelial cell precur-
sors require FOXN1 for full differentiation into
cortical and medullary thymic epithelial cells capa-
ble of supporting T cell development. In epithelial
cells, FOXN1 contributes to keratinocyte prolifera-
tion and differentiation in hair follicles, and to the
development of the choroid plexus epithelium; this
could explain the major features that characterize
patients with nude/SCID, namely the absence of the
thymus,with a severe T cell defect (thoughnormal B
and NK cells) and abnormal skin development, in-
cluding congenital alopecia and nail dystrophy. The
syndrome belongs to the T–B+NK+ subgroup of
SCIDs.81 Usually, there is a significant reduction of
CD3+CD4+ T helper lymphocytes, while the num-
ber of CD3+CD8+ T cells is less reduced. Function-
ally, there is a severe impairment of the proliferative
response to mitogens, as found in the other forms
of SCIDs.
The mutations described in nude/SCID cause a
complete absence of functional FOXN1protein. The
first known mutation identified in humans, R255X,
truncates the protein before the start of the forkhead
domain, while a secondmutation, R320W, leads to a
substitution in the protein’s DNA binding domain.
A third mutation, c.562delA, results in a frameshift
and premature truncation of the protein (p.S188fs)
after thefirst 24aminoacidsof the forkheaddomain.
The disease is inherited as an autosomal recessive
trait.Heterozygous patients showminor ectodermal
anomalies, such as nail dystrophy and, in particular,
leukonychia or koilonychia (spoon nail).86,87 Recent
studies support a role for FOXN1 as cofactor in
the development and differentiation of the central
nervous system.88
Bonemarrow transplantation (BMT) to treat this
nude/SCID, despite the favorable clinical course,
often results in a progressive decline of the CD4+
T cell compartment89 owing to the fact that a nor-
mal thymus is necessary for the generation of the
CD4+ naive subset. Conversely, the production of
CD8+ naive lymphocytes after BMT is less thymus
dependent and even occurs in nude/SCID patients.
In addition, a recent study showed the presence of T
lymphocytes in aFOXN1–/– human fetus, suggesting
partial T cell ontogeny in a thymus- and FOXN1-
independent process.90 Thymus transplantation has
been shown to lead to immune reconstitution in
two nude/SCID patients affected with disseminated
BacillusCalmette-Gue´rin infectionandcytopenia.91
Before the identification of human nude/SCID,
the DiGeorge syndrome (DGS) was long consid-
ered the model of a severe T cell differentiation
defect. DGS is a complex disorder that typically
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comprises T cell deficiency due to thymic hypo/
aplasia, hypoparathyroidism, conotruncal cardiac
defects, facial abnormalities, cognitive defects,
speech delay, other birth defects, and gastrointesti-
nal disorders.92 Deletion of 22q11.2 is the most fre-
quent chromosomal change associated with DGS,93
with an incidence of one in 4000–5000 live births.
The alteration is inherited in a familial autosomal
dominant pattern in 8–28% of the cases.94 Most pa-
tients have a deletion of 3 Mb that includes about
30 genes, while in 8% of the cases a smaller dele-
tion of 1.5 Mb containing 24 genes is detected. No
specific genotype–phenotype relationship has been
documented. Both deletions include the gene T-
box transcription factor 1 (TBX1), which seems to
be necessary for normal development of the thymus
and parathyroid, the large arteries of heart, and the
muscles and bones of face and neck. Thymic hy-
poplasia, responsible for the thymic dysfunction,
is observed in more than 80% of patients. The
syndrome may be associated with variable T cell
deficiencies, ranging from close to normal T cell
numbers and functions, to complete DGS with a
T–B+NK+ SCID-like phenotype accounting for less
than 1% of DGS.95 Recently, a phenotype charac-
terized by a T–B–NK+ SCID has been described
in two DGS patients with a concomitant Artemis
deficiency.96 Patients with complete DGS, like other
infants with SCID, suffer from severe opportunis-
tic infections and exhibit a high risk of acquired
GVHD if transfused. Furthermore, a few patients
affected with an atypical complete DGS have ma-
ture T cells derived from maternal engraftment or
oligoclonal expansion of memory T cells responsi-
ble for a severe inflammation. These patients may
develop an OS, characterized by erythrodermia,
enteropathy, and lymphadenopathy. On the other
hand, there are also subjects carrying the deletion
who only have a mild phenotype. Some patients di-
agnosed as 22q11.2DS in early childhood remain
clinically asymptomatic and exhibit only minimal
immune alterations. Increased prevalence of atopic
and autoimmune diseases has been reported in
patients with partial deletion syndrome.97 While
normal B, NK, and T cell numbers are frequently
observed in 22q11.2DS individuals, sometimes, a
decrease of CD4+ and CD8+ T lymphocytes may
be found97 due to lower thymic output of the naive
T cell subset, oligoclonal T lymphocyte expansion,98
or altered T cell differentiation. These observations
can be explained by the dysregulation of peripheral
T cell homeostasis due to a defect in IL-7 signal-
ing, crucial for T lymphocyte survival and expan-
sion and for homeostasis of the naive CD4+ T cell
pool. Indeed, subjects with 22q11.2DS show a sig-
nificant decrease ofCD3+ T lymphocytes expressing
IL-7Ra; adults have accelerated conversion of naive
to memory cells, shorter telomeres, and a defect in
the variability of the TCR repertoire.98
A DGS phenotype has been described in pa-
tients carrying a 10p deletion, the clinical features
being almost undistinguishable from 22q11.2DS.
Even though low numbers of T cells, reduced
immunoglobulin,80 and thymus hypoplasia have
been observed in 28% of such patients, none have
been affected with a severe SCID-like phenotype.95
SCID/CIDs associated with syndromic
features
According to the International Union of Immun-
ological Societies (IUIS), there are forms of PID
associated with highly pleomorphic extra-immu-
nological features responsible for complex syn-
dromes with a genetic basis. Typical features of
these syndromes comprise peculiar facial dysmor-
phism, growth delay, microcephaly, and ectodermal
abnormalities. While an increased susceptibility to
autoimmunity and (occasionally) cancer associ-
ated with the depletion of other blood cell lines is
frequently reported, an increased susceptibility to
infections is usually less frequent, and its clinical
relevance is lower than in other PIDs. The patho-
genetic mechanism resides in the involvement of
several genes expressed in multiple cell lines, genes
responsible for both ontogenesis and maturation
of the immune system, as well as morphogenesis
and organogenesis of other organs. Some of these
conditions may be associated with a SCID/CID
phenotype. Several syndromes are included in
this group (Table 3), such DGS and CHARGE
syndrome. Patients with CHARGE syndrome ex-
hibit variable grades of immune defects, ranging
from severe to mild T cell lymphopenia and ab-
normal T cell functionality, sometimes associated
with hypogammaglobulinemia.102 The incidence of
SCID in patients with CHARGE is unknown, even
though it may be, as in DGS, rare.103 These pa-
tients, whose clinical phenotype is characterized by
coloboma, heart defect, atresia choanae, retarded
growth and development, genital hypoplasia, and
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Table 3. Peculiar clinical and laboratory findings in the main genetic syndromes which in a few cases may be
associated with a SCID/CID phenotype
Disorder Genetic defect Clinical phenotype Immunological features
CHARGE syndrome CHD7 Coloboma, hearth defect,
atresia choanae, retarded
growth and development
T–B+NK+ SCID, OS,
T cell lymphopenia,
hypogamma-
globulinemia
Cartilage–hair hypoplasia
(CHH)
RMRP Short limb with metaphyseal
dysostosis, sparse hair,
neural dysplasia of intestine
T cell lymphopenia,
hypogammaglobuline-
mia, antibody
deficiency
Schimke immuno-osseous
dysplasia
SMARCAL1 Short stature, IUGR,
spondiloepiphyseal
dysplasia
T cell lymphopenia, bone
marrow failure
Hyper IgE syndrome PGM3 Short stature, brachydactyly,
facial dysmorphism,
intellectual disability
Congenital leucopenia,
neutropenia, B and
T cell lymphopenia
Hoyeraal-Hreidarsson
syndrome (HHS)
DKC1 Microcephaly, cerebellar
hypoplasia, IUGR
Bone marrow failure, CID
or T+B–NK– SCID
Folate and cobalamin
metabolism defect
PCFT, TCN2,
MTHFD1
Failure to thrive, weakness,
mental retardation,
megaloblastic anemia,
neurological disease
Pancytopenia, SCID-like
phenotype, hypogam-
maglobulinemia
Anhydrotic ectodermic
dysplasia with
immunodeficiency
NEMO Hypohidrosis, hypodontia,
conical teeth, facial
dysmorphism
SCID/CID-like phenotype
IUGR, intrauterine growth restriction.
ear anomalies/deafness, may suffer from a T–B+
NK+ SCID and, in some cases, OS.103 The disor-
der is caused by mutations in the chromodomain
helicase DNA binding protein 7 gene (CHD7), a
member of the chromo domain helicase DNA bind-
ing domain family of adenosine-5′-triphosphate de-
pendent chromatin remodeling enzymes. CHD7
is expressed throughout the neural crest contain-
ing mesenchyme of the pharyngeal arches, suggest-
ing a pathogenetic overlap between CHARGE and
DGS.
In other syndromes, several peculiar skeletric ab-
normalities are the main feature, which lead the pa-
tient to themedical attention, as observed inpatients
with cartilage–hair hypoplasia (CHH), character-
ized by severe disproportionate short stature due
to short limb with metaphyseal dysostosis, sparse
hair and neural dysplasia of the intestine,104 or in
Schimke immuno-osseous dysplasia, which some-
times may show a CID phenotype.
In humans, defects in gene involved in telom-
ere maintenance (TERT, TERC, DKC1, WRAP53/
TCAB1, NOP10, NHP2, and TINF2) are respon-
sible for the dyskeratosis congenita (DC), a rare
congenital disorder characterized by progressive
bone marrow failure, premature aging, mucocuta-
neous abnormalities, and cancer predisposition.106
The most sever infantile variant of X-linked DC is
the Hoyeraal-Hreidarsson syndrome (HHS), whose
main clinical features are microcephaly, cerebellar
hypoplasia, and intrauterine growth retardation.
The early-onset bonemarrow failure usually leads to
either a combined immunodeficiencyor aT+B–NK–
SCID, which may require HSCT.107
Recently, several inborn errors in folate and
cobalamin metabolism have been described as hav-
ing a profound impact on many systems, including
hematopoiesis and neuronal function. Immuno-
deficiency of variable degrees has been associated
with defects in these pathways. A CID phenotype
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characterized by lymphopenia, responsiveness to
folate replacement therapy, and severe bacterial and
viral infections has been described in patients with
functional methionine synthase deficiency caused
by hereditary folatemalabsorption due to deficiency
in the proton coupled folate transporter (PCFT)
and in transcobalamin II (TCN2); this CID usually
presents in early infancy in untreated patients
as failure to thrive, weakness, pancytopenia, and
intellectual disability. Recently, exomic sequencing
demonstrated that heterozygous mutations in the
trifunctional protein MTHFD1 is responsible for
a SCID-like phenotype characterized by T–B–NK–
lymphopenia, marked hypogammaglobulinemia,
megaloblastic anemia, and neurologic disease.108
A partial immune reconstitution after vitamin B12
and folate replacement therapy has been docu-
mented.
In summary, it must be noted that several syn-
dromes, together with the more typical severe man-
ifestations, can share clinical and immunological
signs of SCID/CID, as for example patients affected
by NEMO deficiency.
Recently identified combined
immunodeficiencies
Combined immunodeficiency (CID) is a group of
genetic heterogeneous disorders characterized by
severe recurrent infections, moderate reduction of
T and B lymphocytes, and impaired cellular and
humoral functionality that may reflect late defects
in T cell development and function.109,110 In most
cases, it is not always easy to distinguish between
patients affected with more severe forms and those
with CID. Furthermore, a greater difficulty in mak-
ing a clear classification is due to the fact that many
inborn defects, which underlie these immune dis-
orders, have recently been associated with both
SCID and CID, in particular hypomorphic mu-
tations. Several genetic defects responsible for a
wide number of clinical conditions are comprised
in this group (Table 2).111 Besides the well-known
genetic defects responsible for MHC class I (TAP1,
TAP2, TAPBP) or class II deficiency (CIITA,
RRFX5, RFXAP, RFXANK) associated with a pre-
dominant CD8+ or CD4+ selective deficiency
respectively, the very rare CD8A defects and many
others (see the new International Union of Im-
munological Societies classification, Ref. 111)
have been identified recently. Since the number
of these conditions is large, we have chosen to
discuss only the most common form associated
with new phenotypes and novel ones reported over
the past 3 to 4 years.
ZAP70-related immunodeficiency is inherited in
an autosomal recessive manner. It is caused by ab-
normal TCR signaling, which leads to a selective
absence of CD8+ T cells and normal or elevated
numbers of non-functional CD4+ T cells. ZAP70
has a key role in bothmatureT cell signaling anddif-
ferentiation of thymic precursors. Finally, in some
patients peculiar phenotypes have been observed.
In particular, some patients exhibit an attenuated
phenotype with a late onset disease and preserved
production of CD4+ T follicular helper (TFH),
T helper type I (TH1), TH17, and Treg cells. Immune
dysregulation and severe erythroderma resembling
OS have also been described, characterized by skin
infiltrative lesionswith activatedCD4+ T cells in the
peripheral blood.113
Thanks to next generation sequencing technolo-
gies, which have provided a powerful tool to identify
themolecular cause of PIDsof unknowngenetic ori-
gin, new defects have been detected, even though in
most cases the genetic cause still remains unknown.
Whole-exome sequencing recently demonstrated
the presence of deleterious mutations in the phos-
phoglucomutase 3 gene (PGM3) in three unre-
lated subjects with recurrent infections, congenital
leukopenia, neutropenia, B and T cell lymphope-
nia, and progression to bone marrow failure due to
a congenital disorder of glycosylation (CDG). Two
of the three children also had skeletal anomalies
characterized by short stature, brachydactyly, dys-
morphic facial features, and intellectualdisability.105
Thanks to this technology, Kotlarz et al. identi-
fied in 2013 two distinct homozygous loss of func-
tions mutations in the interleukin-21 receptor gene
(IL21R) in two unrelated children affected with
cryptosporidiosis, chronic cholangitis and liver dis-
ease, recurrent upper and lower airway infections,
and failure to thrive.99 IL-21R binds to common
c and signals via JAK/STAT pathways.100,101 The
authors observed that the mutation was responsi-
ble for the aberrant trafficking of the IL-21R to the
plasma membrane and for the abrogation of IL-21
ligand binding. These molecular alterations lead to
defective phosphorylation of STAT1, STAT3, and
STAT5. The immunophenotype of these patients
was normal, but abnormal proliferation induced by
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IL-21 and defects in immunoglobulin class-
switching in B cells and NK cell cytotoxicity were
documented. A defect in T cell secretion of sev-
eral cytokines, including TH17-associated cytokines
IL-17F and IL-22, was reported, thus putatively
explaining the increased susceptibility to crypto-
sporidial infection in these patients.
In the last few years mutations in the CARD9–
BCL10–MALT1 (CBM) complex involved inNF-B
signaling have been associated with PID. In partic-
ular, autosomal recessive mutations in MALT1 gene
have been described in patients with CID and se-
vere bacterial, fungal and viral infections.114 The
MALT1-deficient T cells are not able to degrade
IB or produce IL-2 following T cell activation.
BCL10 has a role in several immune pathways crit-
ical for the function of the innate and the adaptive
immune systems, and for the response to bacte-
rial and fungal infections. Mutations in BCL10 and
other genes encoding for proteins interacting with
MALT1, such as CARD11 and CARD9, have also
been recently described. Patients with BCL10 defi-
ciency show a profound defect of memory T and
B cells and severe hypogammaglobulinemia, with
a reduction of CD69 and CD25 percentages and
ICOS levels.115 Even though CARD9 deficiency has
been shown to selectively compromise defenses to-
ward a limited number of fungal infections, mu-
tations in CARD11, which plays a crucial role in
the differentiation of both neuronal and immuno-
logic tissues as a scaffold protein, are associated
with a more profound CID characterized by abnor-
mal T cell proliferation to anti-CD3/CD28 stimula-
tion, expansion of late transitional B cells, mature
B cells deficiency, and hypogammaglobulinemia.101
Furthermore, CARD11-deficient T cells do not pro-
duce normal amounts of IL-2 or upregulate the
IL-2 receptor chain (CD25) afterTCRstimulation,
which contributes to Treg cell deficiency in these
patients.
Mutations in tetratricopeptide repeat domain
7A (TTC7A), a member of the large family of
proteins containing the tetratricopeptide repeat
(TPR) domain, have recently been found in
patients affected with CID and multiple intestinal
atresia (MIA).116 MIA is a clinical condition that
can be isolated or may occur in association with
variable grades of immunodeficiency ranging from
SCID to a mild decrease of T cells and partially
preserved thymic function. However, in all these
genetic forms, profound CD8+ T cell lymphopenia,
reflecting the impaired cellular immunity and
the defective thymopoiesis, has been observed.
Severe hypogammaglobulinemia is also frequent. A
higher frequency of bloodstream infections due to
intestinal microbes has also been reported.
The clinical and immunological phenotypes of
Ras homolog family member H gene (RHOH)
deficiency is characterized by naive CD4+ T cell
deficiency, absence of recent thymic emigrants,
increased number of effector memory T cells, re-
stricted T cell repertoire, and reduced in vitro pro-
liferation via CD3 stimulation.117 Expressed mainly
in hematopoietic cells, RhoH is a small GTPase
that mediates interaction between Zap70 and LCK.
RhoHdeficiency determines both alterations in pre-
TCR–mediated signaling and in positive selection,
as observed inZap70 deficiency. Expansion ofmem-
ory T cells has also been observed in other CIDs,
such as deficiency of DOCK8 or MST1. DOCK8
deficiency is an autosomal recessive form of CID
associated with a hyper-IgE phenotype. Viral infec-
tions (especially of the skin) and malignancies are
very common. Lymphopenia of CD4+ and CD8+
T cells, or predominantly CD4+ lymphocytes, may
be found. In addition, DOCK8 deficient patients
exhibit defective differentiation of TH17 cells and a
reduction of B lymphocytes.118
The lymphocyte specific kinase LCK is involved
in the initiation of signaling from the TCR 121
through the adaptor protein unc-119 lipid binding
chaperone (UNC119). Recently, mutations in LCK
or UNC119, which impairs LCK activation and
signaling, have been identified. Main features of
this phenotype include CD4+ T cell lymphope-
nia, a restricted T cell repertoire, and impaired
TCR signaling.122 Patients with LCK deficiency
frequently present with immune dysregulation
and autoimmunity. Mutations in the magnesium
transporter protein1 gene (MAGT1) result in a CID
phenotype characterized by CD4+ lymphopenia
and abnormalT cell proliferation,which are respon-
sible for chronic viral infections and EBV-related
lymphoma, respectively.123 Recently, a CID was ob-
served in four unrelated patients with mutation of
inhibitor of kappa light polypeptide gene enhancer
in B-cells, kinase beta (IKBKB); the patients had se-
vere bacterial, viral, fungal,mycobacterial infections
associated with failure to thrive and neurological
impairment. The immunological phenotype was
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characterized by a/hypogammaglobulinemia and
absence of Treg and  / T cells. Even though T cell
counts were normal, all the patients exclusively
showed naive T and B lymphocytes.124
Newborn screening for SCID
Recently, T cell receptor excision circles (TREC)–
based newborn screening has been implemented
in several countries. Compared with patients iden-
tified by the clinical features, patients identified
through newborn screening programs, similar to
children identified because of a positive familial his-
tory, can receive an early and accurate diagnosis
by one month of life and then undergo HSCT or
gene therapy by 3 months of age, before the oc-
currence of severe complications. This results in a
significantly improved outcome.125,126 The TREC
assay, based on the detection of intracellular accu-
mulation of products derived from process of T cell
receptor gene splicing and rearrangement, is able to
detect several defects, which result in either SCID or
profound T cell lymphopenia that is also seen in
patients affected with 22q11.2DS, CHH, CHARGE,
and AT.127 However, one limitation of the TREC
assay is that it is not able to identify all forms of
CID or atypical SCID. Some genetic disorders, such
as deficiency of ZAP70, late onset ADA, Nijmegen
breakage syndrome, MHC class II deficiency, and
many others, are likely to be missed because TRECs
are usually found at normal levels. The identifica-
tion of kappa-deleting recombination excision cir-
cles (KREC), a sensitive marker of newly formed B
cells, increases the possibility of identifying other
forms of SCID/CID that are associated with low
numbers of B lymphocytes, such asNBS and late on-
setADA. Furthermore, it has been reported that tan-
demmass spectrometry caneasily identify abnormal
purine metabolites in newborns with typical or late
onsetADAandPNPdeficiency,19 thus increasing the
spectrum of disorders detectable through newborn
screening.
Conclusions
SCIDs are a heterogeneous group of syndromes re-
lated to alterations of distinct genes that cause ab-
normalities in the maturation and/or function of
T, B, and/or NK cells. Recently, advances in next
generation DNA sequencing have allowed new gene
identification through whole exome sequencing or
whole genome sequencing of several forms of SCID
and CID of unknown cause. The phenotypic and
the molecular heterogeneity of SCIDs, as revealed
by the expanding phenotypes observed, is making
traditional classification of this group of disorders
very intricate. Frequently, differentmutations in the
same gene can lead to different clinical phenotypes,
such as OS, leaky SCID, or CID, that may even be
inherited with different mechanisms.
In this review we have focused in detail on dif-
ferent forms of SCID and CID, paying attention to
the distinctive peculiar clinical and laboratory fea-
tures, in order to provide information to clinicians
for recognizing and carefully managing these novel
forms of PIDs.
Conflicts of interest
The authors declare no conflicts of interest.
References
1. Kwan, A. et al. 2014. Newborn screening for severe com-
bined immunodeficiency in 11 screening programs in the
United States. JAMA 312: 729–738.
2. Van der Burg, M. et al. 2011. The expanding clinical and
immunological spectrum of severe combined immunode-
ficiency. Eur. J. Pediatr. 170: 561–571.
3. Denianke, K.S. et al. 2001. Cutaneous manifestations of-
maternal engraftment in patients with severe combined
immunodeficiency: a clinicopathologic study. Bone Mar-
row Transplant. 28: 227–233.
4. Palamaro, L. et al. 2012. SCID-like phenotype associated
with an inhibitory autoreactive immunoglobulin. J. Inves-
tig. Allergol. Clin. Immunol. 22: 67–70.
5. Shearer, W.T. et al. 2014. Establishing diagnostic criteria
for severe combined immunodeficiency disease (SCID),
leaky SCID, and Omenn syndrome: the primary immune
deficiency treatment consortiumexperience. J. AllergyClin.
Immunol. 133: 1092–1098.
6. Gaspar, H.B. et al. 2013. How I treat severe combined im-
munodeficiency. Blood 122: 3749–3758.
7. Chinen, J. et al. 2014. Advances in basic and clinical im-
munology in 2013. J. Allergy Clin. Immunol. 133: 967–976.
8. Maggina, P. et al. 2013. Classification of primary immun-
odeficiencies: need for a revised approach? J. Allergy Clin.
Immunol. 131: 292–294.
9. Pannicke, U. et al. 2009. Reticular dysgenesis (aleukocyto-
sis) is caused bymutations in the gene encodingmitochon-
drial adenylate kinase 2. Nat. Genet. 41: 101–105.
10. Lagresle-Peyrou, C. et al. 2009. Human adenylate kinase 2
deficiency causes a profound hematopoietic defect associ-
ated with sensorineural deafness. Nat. Genet. 41: 106–111.
11. Klein, C. 2011. Genetic defects in severe congenital neu-
tropenia: emerging insights into life and death of hu-
man neutrophil granulocytes. Ann. Rev. Immunol. 29:
399–413.
102 Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
Cirillo et al. Severe combined immunodeficiencies
12. Tanimura, A. et al. 2014. Differential expression of ade-
nine nucleotide converting enzymes in mitochondrial in-
termembrane space: a potential role of adenylate kinase
isozyme 2 in neutrophil differentiation. PLoS One 9:
e89916.
13. Dzeja, P. et al. 2009. Adenylate kinase and AMP signaling
networks: metabolic monitoring, signal communication
and body energy sensing. Int. J. Mol. Sci. 10: 1729–1772.
14. Kim, H. et al. 2014. The DUSP26 phosphatase activator
adenylate kinase 2 regulates FADD phosphorylation and
cell growth. Nat. Commun. 5: 1–11.
15. Henderson, L.A. et al. 2013. First reported case of Omenn
syndrome in a patient with reticular dysgenesis. J. Allergy
Clin. Immunol. 131: 1227–1230.
16. Barjaktarevic, I. et al. 2010. Altered functional balance of
Gfi-1 and Gfi-1b as an alternative cause of reticular dysge-
nesis? Med. Hypotheses 74: 445–448.
17. Nyhan, W.L. 2005. Disorders of purine and pyrimidine
metabolism. Mol. Genet. Metab. 86: 25–33.
18. Sauer, A.V. et al. 2012. Autoimmune dysregulation and
purine metabolism in adenosine deaminase deficiency.
Front Immunol. 3: 265.
19. la Marca, G. et al. 2014. The inclusion of ADA-SCID in ex-
panded newborn screening by tandem mass spectrometry.
J. Pharm. Biomed. Anal. 88: 201–206.
20. Vihinen, M. et al. 2001. Primary immunodeficiency muta-
tion databases. Adv. Genet. 43: 103–188.
21. Malacarne, F. et al. 2005. Reduced thymic output, increased
spontaneous apoptosis and oligoclonal B cells in polyethy-
lene glycol-adenosine deaminase-treated patients. Eur.
J. Immunol. 35: 3376–3386.
22. Kameoka, J. et al. 1993. Direct association of adenosine
deaminase with a T cell activation antigen, CD26. Science
261: 466–469.
23. Hershfield, M. 2006. Adenosine deaminase deficiency.
Gene Rev. [Internet]. http://www.ncbi.nlm.nih.gov/books/
NBK1483/
24. Santisteban, I. et al. 1993. Novel splicing, missense, and
deletionmutations in seven adenosine deaminase-deficient
patients with late/delayed onset of combined immunode-
ficiency disease: contribution of genotype to phenotype.
J. Clin. Invest. 92: 2291–2302.
25. Shovlin, C.L. et al. 1993. Adult presentation of adenosine
deaminase deficiency. Lancet. 341: 1471.
26. Arredondo-Vega, F.X. et al. 1998. Adenosine deaminase
deficiency: genotype-phenotype correlations based on ex-
pressed activity of 29 mutant alleles. Am. J. Hum. Genet.
63: 1049–1059.
27. Booth, C. et al. 2007. Management options for adenosine
deaminase deficiency: proceedings of the EBMT satellite
workshop (Hamburg, March 2006). Clin. Immunol. 123:
139–147.
28. Gaspar, H.B. et al. 2006. Successful reconstitution of im-
munity in ADA-SCID by stem cell gene therapy following
cessation of PEG-ADA and use of mild preconditioning.
Mol. Ther. 14: 505–513.
29. Aiuti, A. et al. 2009. Gene therapy for immunodeficiency
due to adenosine deaminase deficiency. N. Engl. J. Med.
360: 447–458.
30. Somech,R. et al. 2013.Purinenucleosidephosphorylasede-
ficiency presenting as severe combined immune deficiency.
Immunol. Res. 56: 150–154.
31. Aytekin, C. et al. 2010. Kostmann disease with devel-
opmental delay in three patients. Eur. J. Pediatr. 169:
759–62.
32. Alangari, A. et al. 2009. Purine nucleoside phosphorylase
deficiency in two unrelated Saudi patients.Ann. SaudiMed.
29: 309–312.
33. Dror, Y. et al. 2004. Purine nucleoside phosphorylase de-
ficiency associated with a dysplastic marrow morphology.
Pediatr. Res. 55: 472–477.
34. Grunebaum, E. et al. 2004. Novel mutations and hot-spots
in patients with purine nucleoside phosphorylase defi-
ciency.NucleosidesNucleotidesNucleicAcids 23: 1411–1415.
35. Markert, M.L. 1991. Purine nucleoside phosphorylase de-
ficiency. Immunodefic. Rev. 3: 45–81.
36. Puel, A. et al. 2000. Mutations in the gene for the IL-7 re-
ceptor result in T(-)B(+)NK(+) severe combined immun-
odeficiency disease. Curr. Opin. Immunol. 12: 468–473.
37. Puel, A. et al. 1998. Defective IL-7R expression in
T(-)B(+)NK(+) severe combined immunodeficiency.Nat.
Genet. 20: 394–397.
38. Notarangelo, L.D. et al. 2009. Primary immunodeficiencies:
2009 update. J. Allergy Clin. Immunol. 124: 1161–1178.
39. Notarangelo, L.D. et al. 2000. Of genes and phenotypes: the
immunological and molecular spectrum of combined im-
mune deficiency: defects of the gamma(c)-JAK3 signaling
pathway as a model.Immunol. Rev. 178: 39–48.
40. Du, C. et al. 2005. IL-2-mediated apoptosis of kidney tubu-
lar epithelial cells is regulated by the caspase-8 inhibitor
c-FLIP. Kidney Int. 67: 1397–1409.
41. Ozawa, A. et al. 2004. Endogenous IL-15 sustains re-
cruitment of IL-2Rbeta and common gamma and IL-2-
mediated chemokine production in normal and inflamed
human gingival fibroblast. J. Immunol. 173: 5180–5188.
42. Adriani, M. et al. 2006. Functional interaction of common
gamma chain and growth hormone receptor signaling ap-
paratus. J. Immunol. 177: 6889–6895.
43. Vigliano, I. et al. 2011.  Chain transducing element: a
shared pathway between endocrine and immune system.
Cell Immunol. 269: 10–15.
44. Amorosi, S. et al. 2009. The cellular amount of the common
g-chain influences spontaneous or induced cell prolifera-
tion. J. Immunol. 182: 3304–3309.
45. Kawamura, M. et al. 1994. Molecular cloning of L-JAK, a
Janus family protein-tyrosine kinase expressed in natural
killer cells and activated leukocytes. Proc. Natl. Acad. Sci.
U.S.A. 91: 6374–6378.
46. Rane, S.G. et al. 1994. JAK3: a novel JAK kinase associ-
ated with terminal differentiation of hematopoietic cells.
Oncogene 9: 2415–2423.
47. Notarangelo, L. 1996. Immunodeficiencies caused by ge-
netic defects in protein kinases. Curr. Opin. Immunol. 8:
448–453.
48. Schumacher, R.F. et al. 2000. Complete genomic organi-
zation of the human JAK3 gene and mutation analysis in
severe combined immunodeficiency by single-strand con-
formation polymorphism. Hum. Genet. 106: 73–79.
103Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
Severe combined immunodeficiencies Cirillo et al.
49. Waldmann, T.A. 2006. The biology of interleukin-2 and
interleukin-15: implications for cancer therapy and vaccine
design. Nat. Rev. Immunol. 6: 595–601.
50. Leonard, W.J. 1996. The molecular basis of X-linked severe
combined immunodeficiency: defective cytokine receptor
signaling. Ann. Rev. Med. 47: 229–239.
51. Ban, S.A. et al. 2014. Combined immunodeficiency evolv-
ing into predominant CD4+ lymphopenia caused by so-
matic chimerism in JAK3. J. Clin. Immunol. 34: 941–953.
52. DiSanto, J.P. et al. 1995. Lymphoid development in mice
with a targeteddeletionof the interleukin2 receptor gamma
chain. Proc. Natl. Acad. Sci. U.S.A. 92: 377–381.
53. Stephan, V. et al. 1996. Atypical X-linked severe combined
immunodeficiency due to possible spontaneous reversion
of the genetic defect in T cells. N. Engl. J. Med. 335:
1563–1567.
54. Wada, T. et al. 2008. Detection of T lymphocytes with a
second-sitemutation in skin lesions of atypical X-linked se-
vere combined immunodeficiencymimickingOmenn syn-
drome. Blood 112: 1872–1875.
55. Slatter, M.A. et al. 2011. Polymorphous lymphoprolif-
erative disorder with Hodgkin-like features in common
gamma chain-deficient severe combined immunodefi-
ciency. J. Allergy Clin. Immunol. 127: 533–535.
56. Patiroglu, T. et al. 2014. X-linked severe combined im-
munodeficiency due to a novel mutation complicated with
hemophagocytyc lymphohistiocytosis and presented with
invagination: a case report. Eur. J. Microbiol. Immunol. 3:
174–176.
57. Grunebaum, E. et al. 2000. Haemophagocytic lymphohis-
tiocytosis in X-linked severe combined immunodeficiency.
Br. J. Haematol. 108: 834–837.
58. Dvorak, C.C. et al. 2008. Maternal T-cell engraftment as-
sociated with severe hemophagocytosis of bone maroow
in untreated X-linked severe combined immunodeficiency.
J. Pediatr. Hematol. Oncol. 30: 396–400.
59. Lynch, M. et al. 1992. The interleukin-7 receptor gene is at
5p13. Hum. Genet. 89: 566–568.
60. Yu, Q. et al. 2003. In vitro evidence that cytokine receptor
signals are required for differentiation of double positive
thymocytes into functionally mature CD8+ T cells. J Exp.
Med. 197: 475–487.
61. Giliani, S. et al. 2006. Interleukin-7 receptor a (IL-7Ra)
deficiency: cellular and molecular bases. Analysis of clin-
ical, immunological, and molecular features in 16 novel
patients. J. Pediatr. 148: 272–274.
62. Zago,C.A. et al. 2014.Autoimmunemanifestations in SCID
due to IL-7Rmutations: Omenn syndrome and cytopenias.
Hum. Immunol. 75: 662–666.
63. Bassing, C.H. et al. 2002. The mechanism and regulation
of chromosomal V(D)J recombination. Cell 109: S45–S55.
64. Woodbine, L. et al. 2013. PRKDC mutations in a SCID
patient with profound neurological abnormalities. J. Clin.
Invest. 123: 2969–2980.
65. Cagdas, D. et al. 2012. Two SCID cases with Cernunnos-
XLF deficiency successfully treated by haematopoietic stem
cell transplantation. Pediatr. Transplant. 16: 167–171.
66. Schwarz, K. et al. 2003. Human severe combined immune
deficiency and DNA repair. Bioassays 25: 1061–1070.
67. Aloj, G. et al. 2012. Severe combined immunodeficiences:
new and old scenarios. Int. Rev. Immunol. 31: 43–65.
68. Noordzij, J.G. et al. 2003. Radiosensitive SCIDpatientswith
Artemis gene mutation schow a complete B-cell differenti-
ation arrest at the pre-B-cell receptor checkpoint in bone
marrow. Blood 101: 1446–1452.
69. Niehues, T. et al. 2010. More than just SCID–the pheno-
typic range of combined immunodeficiencies associated
with mutations in the recombinase activating genes (RAG)
1 and 2. Clin. Immunol. 135: 183–192.
70. Schuetz, C. et al. 2008. An immunodeficiency disease
with RAG mutations and granulomas. N. Engl. J. Med. 8:
2030–2038.
71. Lee, Y.N. et al. 2014. A systematic analysis of recombina-
tion activity and genotype-phenotype correlation in hu-
man recombination-activating gene 1 deficiency. J. Allergy
Clin. Immunol. 133: 1099–1108.
72. van der Burg, M. et al. 2009. DNA-PKcs deficiency in hu-
man: long predicted, finally found.Curr. Opin. Allergy Clin.
Immunol. 9: 503–509.
73. Turul, T. et al. 2011. Cernunnos deficiency: a case report.
J. Invest Allergol. Clin. Immunol. 21: 313–316.
74. van der Burg, M. et al. 2006. B-cell recovery after stem
cell transplantation of Artemis-deficient SCID requires
elimination of autologous bone marrow precursor-B-cells.
Haematologica 91: 1705–1709.
75. Kung, C. et al. 2000. Mutations in the tyrosine phosphatase
CD45 gene in a child with severe combined immunodefi-
ciency disease. Nat. Med. 6: 343–345.
76. Tokgoz, H. et al. 2013. Variable presentation of primary
immuno deficiency: two cases with CD3 gamma deficiency
presenting with only autoimmunity. Pediatr. Allergy Im-
munol. 24: 257–262.
77. Foger, N. et al. 2006. Requirement for coronin 1 in T lym-
phocyte trafficking and cellular homeostasis. Science 313:
839–842.
78. Shiow, L.R. et al. 2008. The actin regulator coronin 1A is
mutant in a thymic egress-deficient mouse strain and in
a patient with severe combined immunodeficiency. Nat.
Immunol. 9: 1307–1315.
79. Moshous, D. et al. 2013. Whole-exome sequencing iden-
tifies Coronin-1A deficiency in 3 siblings with immunod-
eficiency and EBV-associated B-cell lymphoproliferation.
J. Allergy Clin. Immunol. 131: 1594–1603.
80. Pignata, C. et al. 1996. Progressive deficiencies in blood
T cells associated with a 10p12-13 interstitial deletion.
Clin. Immunol. Immopathol. 80: 9–15.
81. Pignata, C. 2002. A lesson to unraveling complex aspects
of novel immunodeficiencies from the human equivalent
of the nude/SCID phenotype. J. Hematother. Stem Cell Res.
11: 409–414.
82. Romano, R. et al. 2013. FOXN1: a master regulator gene of
thymic epithelial development program. Front Immunol. 4:
187.
83. Palamaro, L. et al. 2014. FOXN1 in organ development and
human diseases. Int. Rev. Immunol. 33: 83–93.
84. Chou, J. et al. 2014. A novelmutation in FOXN1 resultingin
SCID: a case report and literature review. Clin. Immunol.
155: 30–32.
104 Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
Cirillo et al. Severe combined immunodeficiencies
85. Romano, R. et al. 2012. From murine to human Nude/
SCID: the Thymus, T-cell development and the missing
link. Clin. Dev. Immunol. 2012: 467101.
86. Auricchio, L. et al. 2005. Nail distrophy associated
with a heterozygous mutation of the Nude/SCID hu-
man FOXN1 (WHN) gene. Arch. Dermatol. 141: 647–
648.
87. Adriani, M. et al. 2004. Ancestral founder mutation of the
nude (FOXN1) gene in congenital severe combined im-
munodeficiency associated with alopecia in southern Italy
population. Ann. Hum. Genet. 68: 265–268.
88. Amorosi, S. et al. 2008. FOXN1 homozygous mutation
associated with anencephaly and severe neural tube de-
fect in human athymic Nude/SCID fetus. Clin. Genet. 73:
380–384.
89. Pignata, C. et al. 2001. Human equivalent of the mouse
nude/SCID phenotype: long-term evaluation of immuno-
logical reconstitution after bone marrow transplantation.
Blood 97: 880–885.
90. Fusco, A. et al. 2013. Molecular evidence for a thymus-
independent partial T cell development in a FOXN1−/−
athymic human fetus. PLoS One 8: e81786.
91. Markert, M.L. et al. 2011. First use of thymus transplanta-
tion therapy for Foxn1 deficiency (nude/SCID): a report of
two cases. Blood 117: 688–696.
92. Giardino, G. et al. 2014. Gastrointestinal involvment in
patients affected with 22q11.2 deletion syndrome. Scand.
J. Gastroenterol. 49: 274–279.
93. Cancrini, C. et al. 2014. Clinical features and follow-up in
patients with 22q11.2 deletion syndrome. J. Pediatr. 164:
1475–1480.
94. Cirillo, E. et al. 2014. Intergenerational and intrafamilial
phenotypic variability in 22q11.2 deletion syndrome sub-
jects. BMC Med. Genet. 15: 1.
95. Davies, E.G. 2013. Immunodeficiency in DiGeorge syn-
dromeandoption for treating caseswith complete athymia.
Front. Immunol. 4: 322.
96. Heimall, J. et al. 2012. Diagnosis of 22q11.2 deletion
syndrome and artemis deficiency in two children with
T–B–NK+ immunodeficiency. J. Clin. Immunol. 32:
1141–1145.
97. Ferrando-Martinez, S. et al. 2014. Low thymic output, pe-
ripheral homeostasis deregulation, andhastened regulatory
T cells differentiation in children with 22q11.2 deletion
syndrome. J. Pediatr. 164: 882–889.
98. Piliero, L.M. et al. 2004. T-cell homeostasis in humans with
thymic hypoplasia due to chromosome 22q11.2 deletion
syndrome. Blood 103: 1020–1025.
99. Kotlarz, D. et al. 2013. Loss-of-function mutations in the
IL-21 receptor gene cause a primary immunodeficiency
syndrome. J. Exp. Med. 210: 433–443.
100. Spolski, R. et al. 2008. Interleukin-21: basic biology and
implications for cancer and autoimmunity. Ann. Rev. Im-
munol. 26: 57–79.
101. Stepensky, P. et al. 2014. Extending the clinical and im-
munological phenotype of human Interleukin-21 receptor
deficiency. Haematologica 99: e72–e76.
102. Jyonouchi, S. et al. 2009. CHARGE syndrome and chro-
mosome 22q11.2 deletion syndrome: a comparison of
immunologic and non-immunologic phenotypic features.
Pediatrics 123: e871–e877.
103. Gennery, A.R. et al. 2008. Mutations in CHD7 in patients
with CHARGE syndrome cause T−B+NK+ severe com-
bined immune deficiency and may cause Omenn-like syn-
drome. Clin. Exp. Immunol. 153: 75–80.
104. Roifman, C.M. et al. 2006. Mutations in the RNA compo-
nent of RNase mitochondrial RNA processing might cause
Omenn syndrome. J. Allergy Clin. Immunol. 117: 897–903.
105. Zhang, Y. et al. 2014. Autosomal recessive phosphogluco-
mutase 3 (PGM3) mutations link glycosilation defects to
atopy, immune deficiency, autoimmunity, and neurocog-
nitive impairment. J. Allergy Clin. Immunol. 133: 1400–
1409.
106. Touzot, F. et al. 2012.Heterogeneous telomere defects in pa-
tients with severe forms of dyskeratosis congenita. J. Allergy
Clin. Immunol. 129: 473–82.
107. Cossu, F. et al. 2002. A novel DKC1 mutation, se-
vere combined immunodeficiency (T+B−NK− SCID) and
bone marrow transplantation in an infant with Hoyeraal-
Hreidarsson syndrome. Br. J. Haematol. 119: 765–768.
108. Keller, M.D. et al. 2013. Severe combined immunodefi-
ciency resulting from mutations in MTHFD1. Pediatrics
131: e629–e634.
109. Notarangelo, L. 2013. Functional T cell immunodeficien-
cies (with T cells present).Ann. Rev. Immunol. 31: 195–225.
110. Roifman, C.M. et al. 2012. Defining combined immunod-
eficiency. J. Allergy Clin. Immunol. 130: 177–183.
111. Al-Herz, W. et al. 2014. Primary immunodeficiency dis-
eases: an update on the classification from the Interna-
tional union of immunological societies expert committee
for primary immunodeficiency. Front. Immunol. 5: 460.
112. Elder, M.E. et al. 1994. Human severe combined immun-
odeficiency due to a defect in ZAP-70, a T cell tyrosine
kinase. Science 264: 1596–1598.
113. Turul, T. et al. 2009. Clinical heterogeneity can hamper the
diagnosis of patients with ZAP70 deficiency. Eur. J. Pediatr.
168: 87–93.
114. Jabara, H.H. et al. 2013. A homozygous mucosa-associated
lymphoid tissue 1 (MALT1) mutation in a family with
2 combined immunodeficiency. J. Allergy Clin. Immunol.
132: 151–158.
115. Torres, J.M. et al. 2014. Inherited BCL10 deficiency impairs
hematopoietic and nonhematopoietic immunity. J. Clin.
Invest. 124: 5239–5248.
116. Chen, R. et al. 2013. Whole exome sequencing identi-
fies TTC7A mutations for combined immunodeficiency
with intestinal atresias. J. Allergy Clin. Immunol. 132: 656–
664.
117. Yang, J. et al. 2009. Activation of Rho GTPases by DOCK
exchange factors ismediated by a nucleotide sensor. Science
325: 1398–1402.
118. Zhang, Q. et al. 2009. Combined immunodeficiency as-
sociated with DOCK8 mutations. N. Engl. J. Med. 361:
2046–2055.
119. Huck, K. et al. 2009. Girls homozigous for an IL-2 inducible
T cell kinase mutation that leads to protein deficiency
develop fatal EBV-associated lymphoproliferation. J Clin.
Invest. 119: 1350–1358.
105Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
Severe combined immunodeficiencies Cirillo et al.
120. Picard, C. et al. 2009. STIM1 mutation associated with
a syndrome of immunodeficiency and autoimmunity.
N. Engl. J. Med. 360: 1971–1980.
121. Goldman, F.D. et al. 1998. Defective expression of p56lck in
an infant with severe combined immunodeficiency. J. Clin.
Invest. 102: 421–429.
122. Gorska, M. et al. 2012. Consequences of a mutation
in the UNC119 gene for T cell function in idiopathic
CD4 lymphopenia. Curr. Allergy Asthma Rep. 12: 396–
401.
123. Li, F.Y. et al. 2011. Loss of MAGT1 abrogates, the
Mg2+ flux required for T cell signaling and leads to a
novel human primary immunodeficiency.Magnes. Res. 24:
S109–S114.
124. Pannicke, U. et al. 2013. Deficiency of innate and acquired
immunity caused by an IKBKB mutation. N. Engl. J. Med.
369: 2504–2514.
125. Dvorak, C.C. et al. 2013. The natural history of children
with severe combined immunodeficiency: baseline features
of the first fifty patients of the primary immune deficiency
treatment consortium prospective study 6901. J. Clin. Im-
munol. 33: 1156–1164.
126. Gaspar, H.B. et al. 2014. The case for mandatory newborn
screening for severe combined immunodeficiency (SCID).
J. Clin. Immunol. 34: 393–397.
127. Verbsky, J. et al. 2014. Screenings for and treatment of
congenital immunodeficienciency diseases. Clin. Perinatol.
41: 1001–1015.
106 Ann. N.Y. Acad. Sci. 1356 (2015) 90–106 C© 2015 New York Academy of Sciences.
